Edition:
United States

Shionogi & Co Ltd (4507.T)

4507.T on Tokyo Stock Exchange

5,777JPY
24 Mar 2017
Change (% chg)

¥143 (+2.54%)
Prev Close
¥5,634
Open
¥5,647
Day's High
¥5,780
Day's Low
¥5,634
Volume
1,333,800
Avg. Vol
1,263,539
52-wk High
¥6,304
52-wk Low
¥4,537

4507.T

Chart for 4507.T

About

Shionogi & Co., Ltd. is a Japan-based pharmaceutical company. It is engaged in the research, development, purchase, manufacture and sale of pharmaceuticals, as well as pharmaceutical-related businesses. The Company mainly provides vitamin preparations, analgesic antipyretics, cold and sinus medicine, digestive medicine,... (more)

Overall

Beta: 0.96
Market Cap(Mil.): ¥1,901,420.00
Shares Outstanding(Mil.): 329.14
Dividend: 34.00
Yield (%): 1.18

Financials

  4507.T Industry Sector
P/E (TTM): 20.53 29.17 29.94
EPS (TTM): 281.46 -- --
ROI: 16.37 13.48 13.01
ROE: 18.16 14.39 14.16

Gilead challenges GSK with strong HIV drug data

LONDON Gilead Sciences has thrown down a challenge to GlaxoSmithKline with good clinical trial results for an experimental HIV drug that works in the same way as the British group's successful dolutegravir.

Feb 14 2017

Gilead challenges GSK with strong HIV drug data

LONDON, Feb 14 Gilead Sciences has thrown down a challenge to GlaxoSmithKline with good clinical trial results for an experimental HIV drug that works in the same way as the British group's successful dolutegravir.

Feb 14 2017

GlaxoSmithKline and Gilead to face off at HIV meeting next week

LONDON GlaxoSmithKline and Gilead Sciences will vie for business in treating HIV patients next week when both companies unveil clinical trial results at a medical meeting in Seattle.

Feb 08 2017

GlaxoSmithKline and Gilead to face off at HIV meeting next week

LONDON, Feb 8 GlaxoSmithKline and Gilead Sciences will vie for business in treating HIV patients next week when both companies unveil clinical trial results at a medical meeting in Seattle.

Feb 08 2017

BRIEF-Takeda Pharmaceutical and Shionogi & Co to develop treatment techniques to combat Dementia- Nikkei

* Takeda Pharmaceutical and Shionogi & Co. with three other Japanese drug companies to develop treatment techniques to combat Dementia

Jan 30 2017

BRIEF-R&I affirms Shionogi & Co Ltd's rating at "A+" and announces stable outlook - R&I

* Rating and Investment Information, Inc. (R&I) affirmed the company's rating at "A+" - R&I

Jan 19 2017

BRIEF-Shionogi & retires 22 mln treasury shares on Jan. 10

* Says the co retired 22 million shares(6.3 percent stake) of its common stock on Jan. 10

Jan 10 2017

GSK's two-drug HIV therapy shines in two big studies

LONDON GlaxoSmithKline's already fast-growing HIV drug business has received an important boost after two major clinical studies successfully tested a new two-drug treatment regimen to control the virus that causes AIDS.

Dec 20 2016

GSK insider Waterhouse to head drugmaker's HIV unit ViiV

LONDON GlaxoSmithKline said on Monday that Dominique Limet would step down at the end of March 2017 as head of the drugmaker's majority-owned HIV business ViiV Healthcare, to be replaced by GSK insider Deborah Waterhouse.

Dec 05 2016

BRIEF-Shionogi & announces decision of patent revocation and patent infringement actions in UK

* Says the co filed a counterclaim in patent court in the UK stating that Merck Sharp & Dohme Limited's "integrase inhibitor Isentress" infringes the co's UK patent on May 16, 2015

Nov 27 2016

More From Around the Web

Earnings vs. Estimates